The Brewton Standard
Small Business - The Brewton Standard | The Brewton Standard
...on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that four scientific abstracts on its lead drug candidate, obefazimod, for the treatment of moderately to severely active ulcerative colitis (UC) and in a preclinical model on colon cancer, will be presented at Digestive Disease Week (DDW) as part of scientific exchange, taking place May 18-21, 2024, in Washington D.C., U.S...
1 day ago